Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 08 2019
Historique:
received: 03 12 2018
revised: 16 04 2019
accepted: 19 06 2019
pubmed: 27 6 2019
medline: 17 6 2020
entrez: 27 6 2019
Statut: ppublish

Résumé

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. To identify TNBC therapeutic targets, we performed integrative bioinformatics analysis of multiple breast cancer patient-derived gene expression datasets and focused on kinases with FDA-approved or in-pipeline inhibitors. Sphingosine kinase 1 (SPHK1) was identified as a top candidate. SPHK1 overexpression or downregulation in human TNBC cell lines increased or decreased spontaneous metastasis to lungs in nude mice, respectively. SPHK1 promoted metastasis by transcriptionally upregulating the expression of the metastasis-promoting gene

Identifiants

pubmed: 31239273
pii: 0008-5472.CAN-18-3803
doi: 10.1158/0008-5472.CAN-18-3803
pmc: PMC6697620
mid: NIHMS1532907
doi:

Substances chimiques

Carrier Proteins 0
FSCN1 protein, human 0
Microfilament Proteins 0
NF-kappa B 0
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-
sphingosine kinase EC 2.7.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4211-4226

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA112567
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184836
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Methods Enzymol. 2000;311:215-23
pubmed: 10563328
Curr Biol. 2000 Nov 30;10(23):1527-30
pubmed: 11114522
Cancer Res. 2001 May 1;61(9):3535-40
pubmed: 11325813
Exp Cell Res. 2002 Nov 15;281(1):115-27
pubmed: 12441135
Nat Rev Mol Cell Biol. 2003 May;4(5):397-407
pubmed: 12728273
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
Cancer Res. 2004 May 15;64(10):3479-85
pubmed: 15150101
Curr Opin Cell Biol. 2004 Oct;16(5):590-6
pubmed: 15363811
Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804
pubmed: 16002322
FEBS Lett. 2005 Oct 10;579(24):5313-7
pubmed: 16194537
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Biochim Biophys Acta. 2006 Dec;1758(12):2016-26
pubmed: 16996023
BMC Cancer. 2006 Oct 09;6:241
pubmed: 17029629
Nat Methods. 2007 Apr;4(4):359-65
pubmed: 17396127
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Curr Drug Targets. 2008 Aug;9(8):662-73
pubmed: 18691013
FASEB J. 2009 Feb;23(2):405-14
pubmed: 18824518
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Cancer Treat Rev. 2010 May;36(3):206-15
pubmed: 20060649
Curr Biol. 2010 Feb 23;20(4):339-45
pubmed: 20137952
Nature. 2010 Apr 15;464(7291):1062-6
pubmed: 20393565
Nat Rev Cancer. 2010 Jul;10(7):489-503
pubmed: 20555359
Nature. 2010 Jun 24;465(7301):1084-8
pubmed: 20577214
Int J Biochem Cell Biol. 2010 Oct;42(10):1614-7
pubmed: 20601080
Commun Integr Biol. 2010 May;3(3):263-70
pubmed: 20714410
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S80-6
pubmed: 21129616
Trends Pharmacol Sci. 2011 Jan;32(1):16-24
pubmed: 21159389
Oncogene. 2011 Oct 27;30(43):4437-46
pubmed: 21532620
Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26
pubmed: 21697900
J Transl Med. 2011 Sep 22;9:157
pubmed: 21936950
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Biochem J. 2012 May 15;444(1):79-88
pubmed: 22397330
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Int J Colorectal Dis. 2012 Dec;27(12):1569-78
pubmed: 22684547
BMC Med. 2013 Feb 26;11:52
pubmed: 23442983
Am J Physiol Cell Physiol. 2013 Jun 15;304(12):C1187-97
pubmed: 23576579
J Clin Pathol. 2014 Feb;67(2):153-60
pubmed: 23986556
Am J Pathol. 2013 Oct;183(4):1096-1112
pubmed: 23988612
Joint Bone Spine. 2014 Jul;81(4):325-30
pubmed: 24561023
Oncotarget. 2014 Aug 15;5(15):5920-33
pubmed: 25153718
Clin Cancer Res. 2015 Jan 15;21(2):417-27
pubmed: 25411162
Cancer Cell. 2015 Feb 9;27(2):177-92
pubmed: 25670079
Trends Pharmacol Sci. 2015 Jul;36(7):422-39
pubmed: 25975227
Breast Cancer Res. 2016 Jan 27;18(1):13
pubmed: 26818199
Oncotarget. 2016 Dec 6;7(49):80579-80585
pubmed: 27811358
Cell Signal. 2017 Apr;32:85-92
pubmed: 28108260
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Immunobiology. 1995 Jul;193(2-4):193-203
pubmed: 8530143

Auteurs

Sunil Acharya (S)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Biology Program, The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas.

Jun Yao (J)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ping Li (P)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Chenyu Zhang (C)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Frank J Lowery (FJ)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Biology Program, The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas.

Qingling Zhang (Q)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Hua Guo (H)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jingkun Qu (J)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Fei Yang (F)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ignacio I Wistuba (II)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Helen Piwnica-Worms (H)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Aysegul A Sahin (AA)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Dihua Yu (D)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. dyu@mdanderson.org.
Cancer Biology Program, The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH